Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
12 2020
Historique:
received: 26 06 2020
revised: 05 08 2020
accepted: 18 08 2020
pubmed: 28 8 2020
medline: 15 12 2020
entrez: 28 8 2020
Statut: ppublish

Résumé

Observational data suggest an acquired prothrombotic state may contribute to the pathophysiology of COVID-19. These data include elevated D-dimers observed among many COVID-19 patients. We present a retrospective analysis of admission D-dimer, and D-dimer trends, among 1065 adult hospitalized COVID-19 patients, across 6 New York Hospitals. The primary outcome was all-cause mortality. Secondary outcomes were intubation and venous thromboembolism (VTE). Three-hundred-thirteen patients (29.4%) died, 319 (30.0%) required intubation, and 30 (2.8%) had diagnosed VTE. Using Cox proportional-hazard modeling, each 1 μg/ml increase in admission D-dimer level was associated with a hazard ratio (HR) of 1.06 (95%CI 1.04-1.08, p < 0.0001) for death, 1.08 (95%CI 1.06-1.10, p < 0.0001) for intubation, and 1.08 (95%CI 1.03-1.13, p = 0.0087) for VTE. Time-dependent receiver-operator-curves for admission D-dimer as a predictor of death, intubation, and VTE yielded areas-under-the-curve of 0.694, 0.621, and 0.565 respectively. Joint-latent-class-modeling identified distinct groups of patients with respect to D-dimer trend. Patients with stable D-dimer trajectories had HRs of 0.29 (95%CI 0.17-0.49, p < 0.0001) and 0.22 (95%CI 0.10-0.45, p = 0.0001) relative to those with increasing D-dimer trajectories, for the outcomes death and intubation respectively. Patients with low-increasing D-dimer trajectories had a multivariable HR for VTE of 0.18 (95%CI 0.05-0.68, p = 0.0117) relative to those with high-decreasing D-dimer trajectories. Time-dependent receiver-operator-curves for D-dimer trend as a predictor of death, intubation, and VTE yielded areas-under-the-curve of 0.678, 0.699, and 0.722 respectively. Although admission D-dimer levels, and D-dimer trends, are associated with outcomes in COVID-19, they have limited performance characteristics as prognostic tests.

Identifiants

pubmed: 32853982
pii: S0049-3848(20)30470-9
doi: 10.1016/j.thromres.2020.08.032
pmc: PMC7439969
pii:
doi:

Substances chimiques

Fibrin Fibrinogen Degradation Products 0
fibrin fragment D 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

99-105

Subventions

Organisme : NCI NIH HHS
ID : P30 CA196521
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Am J Respir Crit Care Med. 2020 May 15;201(10):1297-1299
pubmed: 32203672
Life Sci. 2020 Aug 1;254:117788
pubmed: 32475810
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Chest. 2002 Apr;121(4):1262-8
pubmed: 11948062
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
J Vasc Surg. 2020 Sep;72(3):799-804
pubmed: 32417304
Blood. 2020 Jul 23;136(4):489-500
pubmed: 32492712
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Thromb Haemost. 2020 Jun;18(6):1517-1519
pubmed: 32294295
Am J Clin Pathol. 2020 May 5;153(6):725-733
pubmed: 32275742
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
J Thromb Haemost. 2020 Aug;18(8):2060-2063
pubmed: 32302462
J Thromb Haemost. 2020 Jun;18(6):1324-1329
pubmed: 32306492
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Thromb Haemost. 2020 Aug;18(8):2075-2076
pubmed: 32470213
JAMA Netw Open. 2020 May 1;3(5):e2010478
pubmed: 32469410
J Thromb Thrombolysis. 2020 Apr 3;:
pubmed: 32246317
Adv Med Sci. 2020 Mar;65(1):97-101
pubmed: 31923773
N Engl J Med. 2020 May 14;382(20):e60
pubmed: 32343504

Auteurs

Leonard Naymagon (L)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America. Electronic address: leonard.naymagon@mountsinai.org.

Nicole Zubizarreta (N)

Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Jonathan Feld (J)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Maaike van Gerwen (M)

Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, United States of America; Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, United States of America.

Mathilda Alsen (M)

Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, United States of America.

Santiago Thibaud (S)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Alaina Kessler (A)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Sangeetha Venugopal (S)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Iman Makki (I)

Department of Medicine, Icahn School of Medicine at Mount Sinai, United States of America.

Qian Qin (Q)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Sirish Dharmapuri (S)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Tomi Jun (T)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Sheena Bhalla (S)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Shana Berwick (S)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Krina Christian (K)

Department of Pathology and Laboratory Medicine, Icahn School of Medicine at Mount Sinai, United States of America.

John Mascarenhas (J)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Francine Dembitzer (F)

Department of Pathology and Laboratory Medicine, Icahn School of Medicine at Mount Sinai, United States of America.

Erin Moshier (E)

Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Douglas Tremblay (D)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH